2026 DCAT Global Summit > Speakers
2026 DCAT Global Summit Featured Speakers
Dr. Christine Allen
Intrepid Labs Inc.
CEO & Co-founder, & Professor, University of Toronto
Michael Schorpp
Boehringer Ingelheim
Head of Digital Innovation & AI, Global Regulatory Affairs
Dr. Christine Allen
Dr. Christine Allen is an internationally recognized leader in drug formulation and development, a full professor at the University of Toronto, and CEO and co-founder of Intrepid Labs Inc., where she combines AI, automation, and deep pharmaceutical expertise to accelerate drug formulation and advance proprietary drug delivery technologies. She has published over 180 peer-reviewed papers and serves on the Scientific Leadership Team of the Acceleration Consortium, a University of Toronto initiative supported by $200M from the Canada First Research Excellence Fund. Dr. Allen is a Fellow of the American Institute for Medical and Biological Engineering and the Canadian Academy of Health Sciences, and has held major leadership roles across the field, including President of the Controlled Release Society and the Canadian Society for Pharmaceutical Sciences, and Editor-in-Chief of the Journal of Controlled Release. She was named to the Medicine Maker Power List 2025, recognizing influential pioneers accelerating progress across drug development. Her academic leadership at U of T includes serving as Interim Dean of the Leslie Dan Faculty of Pharmacy and as the inaugural Associate Vice-President and Vice-Provost, Strategic Initiatives.
Steffen Denzinger, PhD
Dr. Steffen Denzinger studied Chemistry in Germany and the US and obtained his PhD 1996 in the field of Supramolecular Chemistry. He then held several positions in R&D, manufacturing and Quality Control/Quality Assurance in companies spun off out of the former Hoechst AG and then in R&D and quality at a mid-sized fine chemical company. 2009 he joined Merck KGaA in the Life Science sector where he serves as Senior Director Life Science Business Development currently. He has been active in EFCG, the association representing the European CDMO and excipients industry both for GMP products such as Active Pharmaceutical Ingredients as well as non GMP products such as Agrochemicals since nearly twenty year and is serving currently as president of EFCG.dia and FDANEWS.
Thomas is also a member of ASTM E55 WK15778 Cleaning Process Development & Validation Team and worked on ASTM E3106 Risk-based Cleaning Validation Process Standard what was published 2018 and updated 2022. Additionally he is an active member of Parenteral Drug Association (PDA) and currently working on Cleaning Validation Process updates like the Technical Report 29.
Based on the participation in different working groups he is a co-author of different publications. Especially the series „Cleaning Validation for the 21st Century“ series on Pharmaceutical online should be named and he published lately in journals like PharmInd in Germany, Bioprocess online and Biopharma International.
Dr. Ayesha Khanna
Dr. Ayesha Khanna is CEO of Addo AI and one of the world’s leading voices on artificial intelligence — not as theory, but as a hands-on tool for transformation.
Over two decades, she has helped Fortune 500 companies and governments operationalize AI at scale, with clients including Johnson & Johnson, Visa, Pfizer, and Mastercard.
She serves on the boards of Johnson Controls (New York Stock Exchange) and NEOM Tonomus in the Middle East, and previously served on the Global Scientific Advisory Board of L’Oréal. Reuters named her one of the world’s Trailblazing Women in Enterprise AI (2026), she was named to Edelman’s Top 50 AI Creators (2025) and Forbes featured her as one of Southeast Asia’s groundbreaking entrepreneur.
A graduate of Harvard, Columbia, and the London School of Economics, Dr. Khanna reaches more than 300,000 leaders and decision-makers across her platforms and newsletters. Her work has been featured in The New York Times, TIME, Harvard Business Review, and Forbes.
Graham Lewis
Graham Lewis is Vice President, Global Pharma Strategy, IQVIA, a global provider of business and market intelligence, advanced analytics, and technology solutions for the bio/pharmaceutical industry. He has over 30 years of experience focusing on strategic issues within the bio/pharmaceutical industry, with particular emphasis on geographical growth opportunities, mergers and acquisitions, portfolio planning, forecasting, and optimal launch planning and execution.
Before entering the bio/pharmaceutical industry, Mr. Lewis had widespread experience in international market research, product management, and business development at major industrial companies such as Philips and Cadbury Schweppes. He has spoken at conferences throughout the world in Europe, North America, Latin America, and the Far East, including China, and is widely sought after for his strategic insights.
Michael Schorpp
Michael leads AI initiatives that actually ship to production, rather than getting stuck in endless proof-of-concept loops. Over a nearly 20-year tenure at Boehringer Ingelheim, he has transformed enterprise AI adoption by proving that small, agile teams can outperform massive organizational structures.
In his previous role as Head of Knowledge Management & AI, Michael and a team of just three people built iQNow, connecting over 800 million documents and reaching 55,000 users across 68 countries. This initiative saved one million work hours in its first 12 months. Most recently, in August 2025, his team launched the pharma industry’s first Agentic AI Assistant for Regulatory Operations into live production.
A former bench scientist and metal band leader, Michael applies a pragmatic philosophy to tech: trust must be designed in from day one, and governance should enable innovation, not block it. He currently shapes industry direction via the CPHI Advisory Board and KingStreet Ventures, advising C-level executives to stop making alignment presentations and start shipping real value.
2026 DCAT Global Summit Session/Panelist Speakers
Anil Kane, PhD
Thermo Fisher Scientific
Global Head of Technical & Scientific Affairs Pharma Services
Kelsey Achenbach
Kelsey Achenbach has been serving the pharmaceutical and specialty chemical industries for more than 20 years, and has a strong passion for improving the lives of patients through partnerships and innovation. Ms. Achenbach has experience in operations management, business development, commercial management, and strategic business transformation. Currently, Ms. Achenbach leads the Global Pharmaceutical and Global Medical Nutrition businesses at dsm-firmenich; leading innovation and development of critical ingredients in parenteral and enteral nutrition while focusing on improving patient access to critical medications. Before joining dsm-firmenich, Ms. Achenbach had extensive experience in supplying and partnering with the pharmaceutical industry; holding strategic leadership roles at Roquette, Celanese, and FMC.
Prior to joining the DCAT Board of Directors, Ms. Achenbach was an active volunteer and advocate for the DCAT organization; holding positions on the Advisory Board and several committees over the past 7 years. Most recently, Ms. Achenbach chaired the Membership Advantage Committee.
In addition to her continued education and certifications in business leadership, Ms. Achenbach holds a B.S. in Chemical Engineering from the University of Minnesota and MBAs from Columbia Business School and London Business School.
Clemente Aguila
Clemente is a seasoned professional with over 25 years of experience spanning Management Consulting, FMCG, and the Pharmaceutical industry. Over the past decade, he has held multiple leadership roles within the Procurement function. He currently serves as Global Lead for procurement activities across the Operations and Corporate categories at Grifols. With direct responsibility for a budget exceeding USD 1 billion within a company generating more than USD 7 billion in annual revenue, Clemente is at the forefront of procurement transformation, building a value-driven organization while consistently delivering sustainable cost savings.
Thomas Altmann
Thomas has 27 years’ experience in cleaning chemistry, cleaning process, cleaning validation and regulatory compliance. As Strategic Global Technical Consultant, he provides technical consultation on cleaning and sanitization processes optimization for pharmaceutical, API, biotechnology and personal care manufacturers globally. In his role Thomas is a subject matter expert in cleaning validation for product contact surfaces across all types of pharmaceutical and personal care production equipment.
During consulting the above mentioned industries he held presentations and workshops at different organizations like IVT (Institute of validation Technology), ISPE (International Society of Pharmaceutical Engineering), Informa LifeScience, KNEX, PMTC (Pharmaceutical Manufacturing Technology Center), Pharmig, EBM India and FDANEWS.
Thomas is also a member of ASTM E55 WK15778 Cleaning Process Development & Validation Team and worked on ASTM E3106 Risk-based Cleaning Validation Process Standard what was published 2018 and updated 2022. Additionally he is an active member of Parenteral Drug Association (PDA) and currently working on Cleaning Validation Process updates like the Technical Report 29.
Based on the participation in different working groups he is a co-author of different publications. Especially the series „Cleaning Validation for the 21st Century“ series on Pharmaceutical online should be named and he published lately in journals like PharmInd in Germany, Bioprocess online and Biopharma International.
Coral Butler
Coral Butler is Group Head of Digitally Enabled Lean Project Delivery (DeLPD) at PM Group, where she leads the global digital strategy and the ideation, creation, and delivery of bespoke digital solutions for clients. Passionate about aligning people, process, and technology, Coral works closely with project teams to design and deploy tools that solve real‑world challenges and deliver measurable value. Her expertise spans cloud‑based BIM and collaboration, lean delivery, digital twins, and lifecycle data handover. With over 20 years’ experience in the AEC sector, Coral operates at the intersection of engineering, innovation, and leadership to unlock the ROI of digital delivery.
Christopher Conway
Chris is a seasoned business executive with a 28-year consistent track record of exceeding goals, developing talent, and change transformation across a variety of industry verticals: aerospace, pharmaceutical/biotech and contract research, development, and manufacturing.
Chris is highly experienced in P&L leadership, sales, and marketing having worked in large and small, public and private equity backed companies. Over the last three decades Chris has exceeded growth goals in various roles at Bio X Cell, Curia, AMRI, Johnson & Johnson, and Dynabil Industries. This experience enables Chris’s deep understanding of all aspects of business.
Currently, Chris serves as CEO of Bio X Cell (BXC). Founded in 1997, BXC is the world’s leading functional antibody solutions provider specializing in large-scale RUO antibody manufacturing and services. With a growing portfolio of 600+ functional grade antibodies as well as industry leading production capacity to scale antibodies from mg’s to grams, BXC serves thousands of customers in over 50 countries – across academia, government and industry – engaged in preclinical drug development research in areas including oncology, immunology, neuroscience and infectious disease.
Prior to BXC, he served as President and R&D Business Unit Head at Curia, a global organization in small molecule and Biologics contract research, development and manufacturing services, serving the pharmaceutical/biotech industry. Chris led the global R&D business, which included all functions and twenty sites with small molecule and Biologics Drug Discovery, Chemical Development, Formulation Development, Clinical and Commercial API and Aseptic Fill/Finish GMP manufacturing capabilities, to combined organic and inorganic revenue growth of six times and EBITDA growth of ten times. Chris has delivered profitable growth through diverse organizational contexts. During his tenure, the company changed from founder led to public company to private equity backed with Chris being the only remaining executive from all three periods.
Chris also served as a Director on the board of Viyash Life Sciences Private Limited, a Carlyle owned company, as well as currently serves as a Director on the Drug, Chemical & Associated Technologies Association, Inc. (DCAT) and BioDuro, an Advent and Bridgewest Group owned company.
Prior to joining AMRI Chris had a successful career at Johnson & Johnson where he served in several commercial roles across J&J’s portfolio of companies. Chris led in numerous internal and external commercial capacities including sales, marketing, and sales operations. During his tenure with J&J Chris exceeded goals each year, received numerous awards including J&J’s Global Standards of Leadership award in 2008, and completed J&J’s leadership development program.
Prior to joining J&J, Chris was with Dynabil Industries, Inc. (now part of Ducommun, Inc.) an Aerospace manufacturing organization, from 1997-2001.
Chris received his B.S. in Marketing & Management from Siena College and his Doctorate of Humane Letters from the Albany College of Pharmacy and Health Sciences. He resides in Saratoga, NY with his wife Christine and three children, Jack, Finn, and Grayson. He currently sits on the President’s Advisory Council at Albany College of Pharmacy, held previous board seats with Siena College’s Board of Advisors, Coaches vs. Cancer and the Alzheimer’s Association and is active in coaching youth sports including lacrosse and basketball.
Fabrice Cornille
Coming soon.
Sucheth Davuluri
Sucheth is an accomplished senior executive with over two decades of experience in the Pharmaceutical sector, combining strategic vision with practical management skills. His multifaceted background spans Business Development, Sales, Marketing, Quality and Operations Management.
Currently serving as the Vice Chairman and Chief Executive Officer of Neuland labs, Sucheth – part of the company’s founding family has been instrumental in shaping a business culture focused on quality and progress towards a healthier world.
Under his leadership as CEO, Neuland Labs has experienced significant growth. Over the 22-year period, he has been with the company, the company’s market cap not only grew from $ 4 Mn to over $ 2 Bn but also earned top ESG ratings and recognition for sustainability. Notably, he has been driving Business Transformation enabling the company to grow revenues at 24% CAGR over the last six years.
Previously, Sucheth served as Production Group Leader at Cummins Inc USA, where he enhanced production efficiency and quality by streamlining processes, reducing waste, and advancing standards from 3-sigma to 6-sigma. He also spearheaded ISO audits, workforce expansion, and profit-sharing plan development.
Since March 2025, Sucheth has held the position of Non-Executive Director on the board of Pattancheru Envirotech Limited (PETL), a company specialising in comprehensive waste management and environmental protection services. He brings extensive hands-on expertise in business transformation—notably implementing holacracy at Neuland, alongside strengths in operations management, process alignment, quality compliance, and marketing strategy formulation.
Sucheth holds an MBA in Operations & Corporate Finance from the University of Notre Dame’s Mendoza College of Business. He began his academic journey with a degree in Mechanical Engineering from CBIT and is an alumnus of Hyderabad Public School. His professional credentials include a Six Sigma Black Belt certification APICS certification and qualification in Theory of Constraints Project Management, reflecting his commitment to operational excellence.
As an active member of YPO (Young Presidents’ Organization), Sucheth engages in peer learning and leadership development within a global network of over 35,000 chief executives representing organizations with collective annual revenues of USD 9 trillion. During his four-year tenure on the YPO Board, he also served as Chapter Chair for the 2019–2020 term.
Aditya Varna Iyer
Coming soon.
Anil Kane, PhD
Dr. Kane has more than 25 years of experience in the science and business of taking molecules through the entire drug development process. His extensive knowledge spans early stage development to scale-up and commercial manufacturing, and includes technical transfers between global sites and drug lifecycle management.
Dr. Kane has more than 30 years of experience in the science and business of taking molecules through the entire drug development process. His extensive knowledge spans early-stage development to scale-up and commercial manufacturing of drug products and includes technical transfers between global sites and drug life cycle management.
Dr. Kane received his Bachelors, Masters and Ph.D. degrees from the Bombay College of Pharmacy, University of Bombay, India, and served as a post-doctoral fellow at the School of Pharmacy, University of Cincinnati, Ohio. He has also earned an executive MBA from Richard Ivey School of Business, University of Western Ontario, Canada. Dr. Kane is a member of various international pharmaceutical professional organizations and is a speaker at many industry events. He has also published many articles in International journals and delivered many talks at meetings and conferences cross the globe.
Dr. Kane is also appointed as an Adjunct Professor at the Leslie Dan School pf Pharmacy, University of Toronto. And he will serve on the faculty as an additional responsibility.
Priya Kumar
Priya Kumar is the Founder & CEO of Sustainable Inc., an execution-focused supply chain consulting firm that partners with biotech, pharmaceutical, and industrial leaders to drive measurable results across procurement, logistics, and S&OP. With over 18 years of experience spanning end to end supply chain work in a variety of industries, including biotech and pharmaceutical verticals, Priya has led raw material procurement strategy, CDMO management, regulated manufacturing, and global supply chain transformation. Priya blends deep operating expertise with AI-enabled, workflow-driven solutions to strengthen supply resilience, optimize cost structures, and accelerate time to market. She also serves as an Adjunct Professor at the University of Texas at Austin, where she teaches operations and supply chain management to the next generation of industry leaders.
Roman Lagoutte, PhD
Roman Lagoutte graduated from the ENSCCF, and the University of Salford, UK. With a keen interest in complex transformations, he pursued his postdoctoral education at the IOCB, in Prague and then the University of Geneva, investigating radical methodologies, enantioselective organocatalysis, and natural product total synthesis.
He joined SpiroChem in 2018 as a research chemist, and was appointed Director of early Process Research and Development, where his group supported biotechs, pharmas and manufacturing organisations in numerous route scouting and process development projects, from new route designs all the way to non-GMP batch delivery.
At the beginning of 2026, he joined Lonza as Senior Principal Scientist where he spearheads the AI-enabled route scouting services, aimed at swiftly transitioning from fit-for-purpose discovery and preclinical synthetic routes to full-blown GMP manufacturing.
Sigma Mostafa, PhD
Sigma Mostafa is a highly experienced biopharmaceutical executive with a track record of driving growth and market expansion, building high performance organizations, and transforming organizational culture. She has extensive technical and management expertise in cell line and process development, tech transfer, validation, and clinical and commercial manufacturing.
Sigma is currently the Chief Scientific Officer at KBI Biopharma. She was previously KBI’s Senior Vice President and Site Head for its largest site and led the site through unparalleled growth and a successful Pre-licensure Inspection. As KBI’s Chief Scientific Officer, she leverages her rich technical expertise in analytics, cell line development, and process development to lead KBI’s innovation globally. She oversees Analytical Services, Process Development, and Cell Line Development
Sigma started her career at Eli Lilly & Co where she led a Cell Culture Process Development team and the Pilot Plant. . Sigma spent 3 years as Manager of Cell Culture Process Development at Organon /Diosynth Biotechnology (currently FujiFilm Diosynth), which was part of Merck at the time. In this role, she led process development, tech transfer, and post-commercialization optimization for mammalian and insect cell cultures.
Sigma earned her Ph.D. in Chemical & Biological Engineering from Northwestern University and her Bachelor’s in Chemical Engineering from the University of Texas at Austin with High Honors.
Jagruti Patel
Jagruti Patel is a senior professional with decades of experience in the biopharmaceutical industry and at Lonza. She plays a pivotal role in bridging operations and commercial teams to drive innovative biologics partnerships. Starting her career at Lonza in Slough as an entry-level R&D scientist, Jagruti has held diverse roles across the global network, including program management, key member of site leadership team, and commercial strategy in locations such as Singapore, Portsmouth, and California. Known for her collaborative leadership and strategic insight, she has been instrumental in shaping customer-centric solutions and fostering a culture of appreciation and growth. Jagruti’s journey at Lonza is not only a testament to her professional achievements but also to the strong community and lifelong relationships she has built along the way.
Arul Ramadurai
Arul has been Axplora’s Chief Commercial Officer since 2022. A Chartered Chemical Engineer from the UK with an MBA from INSEAD, Arul has a near 30-year business career as a General Manager, Executive Coach and Commercial Negotiator. Previously, he led Commercial (Marketing & Sales) and Operational (Technical Operations & Supply Chain) organizations at Novartis, Baxalta & Shire in several countries and has also served as CEO of a Swiss Biologics CDMO. Arul likes to practice his six languages at our sites, while indulging in a conversation or two about the local region and sports, many of which he follows. Outside of work, he is an avid skier and hiker with his family.
Michael Semo
Michael Semo has been serving in the life sciences industry for over 25 years focused on transforming molecules into life changing medicines for patients. Michael is currently accountable for Global External R&D Strategy of Synthetic CMC at Eli Lilly and Company as an Associate Vice President. Mr. Semo has experience in business transformation, supply chain excellence, alliance management, and technical operations.
Over the past 15 years, Michael has been responsible for the design and management of an integrated outsourcing strategy for CMC covering R&D to manufacturing of clinical material supply. Before joining Lilly, he was a chemist at DowElanco. He has been an active member of DCAT since 2012. In addition to his professional achievements, Michael is dedicated to mentoring the next generation of sourcing professionals.
Mr. Semo has a BS in Chemistry from the University of Notre Dame and a Executive Certificate from the Kelley School of Business at Indiana University.
Gijs Vissers
Gijs Vissers is an Executive Committee Member and Head of Supply & Procurement (COO-equivalent) at Nordic Pharma, with full end-to-end accountability for global operations and sustainability across more than 30 markets. He leads integrated operating networks spanning supply chain, procurement, logistics, order-to-cash, operational excellence, and enterprise transformation—guided by a clear conviction that the true customer of the supply chain is the patient.
With over 20 years of international leadership experience across pharma, life sciences, FMCG, and telecom, Gijs operates at the intersection of geopolitics, digitalization, and global value networks, helping organizations move beyond fragmented efficiency toward resilient, patient-centric ecosystems. At Nordic Pharma, he is redefining what it means to master the supply chain—leveraging data, digital platforms, and trust-based partnerships to connect suppliers, manufacturers, regulators, and markets into transparent, end-to-end networks that safeguard access to medicines.
A strong advocate for close cooperation across the industry, he serves as Project Committee Lead at the Pharmaceutical Supply Chain Initiative (PSCI), where he collaborates with global peers to advance responsible sourcing, ethical practices, and collective resilience.
Gijs brings an executive -level perspective on how patient centricity, sustainability, and collaboration are no longer aspirations, but strategic imperatives shaping the future of bio/pharma in an increasingly volatile world.
2026 DCAT Global Summit Case Study Speakers
Dr. Christine Allen
Intrepid Labs Inc.
CEO & Co-founder, & Professor, University of Toronto
Jara Álvarez Aller
Jara Álvarez Aller is the Service Delivery Manager and Healthcare Vertical Lead at HP, bringing over 20 years of experience in leading global, multidisciplinary engineering teams and driving the delivery of embedded software and AI-enabled solutions. She has overseen end-to-end project execution across firmware development, system platform foundations and software AI solutions, owner and expertise in talent leadership and development. Her extensive background covers project management in large-format printing with agile delivery methodologies, and in prior roles at European-scale digital platforms and specific enterprise systems implementation in a pharmaceutical company. Jara holds a degree in computer engineering, complemented by advanced studies in technology and management, providing a solid foundation for her continued contributions to innovation and leadership in the field.
Dr. Andrew Lewis
Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences’ scientific teams and drug development consultants, Andy is responsible for driving efficiency and innovation within our scientific organization, both to better serve our customers and drive growth for the Company. Andy has over 25 years of experience in the pharmaceutical and drug delivery industry and is a member of the Academy of Pharmaceutical Scientists of Great Britain and is a Fellow of the Controlled Release Society. He holds a Ph.D. in Tissue Engineering and a Bachelor of Pharmacy, both from the University of Nottingham.
Timo Liebig, PhD
Timo joined mAbxience in March 2022 as Chief Scientific Officer and member of the Executive Team, overseeing the Research & Development, Process Improvement & Technology Transfer, and Program Management teams within mAbxience. In 2024, he changed direction and is since then responsible for innovation within mAbxience.
Timo is a senior biopharmaceutical development, regulatory and program management expert, with strong commitment to innovation.
In his roles prior to joining mAbxience, Timo held several senior management positions, e.g., at Alvotech (2014-2019), and also worked in the consultancy space advising on biopharmaceutical products of diverse nature, from cell and gene therapy products to innovative and biosimilar monoclonal antibodies and other complex proteins (PharmaLex/Biopharma Excellence, now Cencora; 2020-2022).
Timo holds a PhD degree in biology (Imperial College London), a MSc degree in regulatory affairs for biopharmaceuticals (University of Strassburg), and is also trained relating to business transformation and innovation (global AMP, IE business school, Madrid).
Rodney Rietze, PhD
Rodney Rietze, PhD, is the CEO of Streamline Bio, a biotechnology company pioneering the use of artificial intelligence and precision robotic automation to transform how cell and gene therapies are manufactured. He has over 25 years of global discovery and drug development experience across academic, biotech and large pharmaceutical settings, with a core focus on regenerative medicine, advanced therapies, and biomanufacturing innovation.
He previously served as the co-founder and CEO of iVexSol, a gene therapy vector manufacturing company, and held scientific and leadership roles at Pfizer Regenerative Medicine (UK) and Novartis CGT, as part of the team that launched KymriahÒ, the first FDA-approved CAR-T therapy. His career has focused on bridging the gap between scientific discovery and developing advanced therapies — with particular emphasis on enabling process automation, next generation manufacturing, and broader patient access.
Prior to his transition to industry, Dr. Rietze was a principal investigator and founding member of the Queensland Brain Institute (Australia), authoring seminal works on neural stem cell biology in Science and Nature and receiving numerous awards for his innovative and ground-breaking discoveries. Dr. Rietze holds a PhD from the University of Melbourne, and a MSc/BSc from the University of Calgary, Canada.
Yaman Tobaje
Yaman Tobaje is an accomplished MSAT and Manufacturing Engineer with broad experience in biopharmaceutical manufacturing, cell and gene therapy, and cGMP operations. He has played a key role in driving process improvements, developing and optimizing Manufacturing Execution Systems (MES), and leading technology transfer and large-scale expansion projects. Throughout his career at organizations such as Legend Biotech, National Resilience, and GSK, Yaman has consistently delivered solutions that enhance efficiency, ensure compliance, and support seamless commercialization. Currently pursuing an MBA alongside a Six Sigma Green Belt certification, he brings a unique combination of technical expertise, operational leadership, and strategic perspective to advance innovation and partnership success in the biotech industry.
